Multiple studies have been completed or are currently underway.


Completed Trials

FML-204

The FML-204 study was a prospective study of 41 patients to evaluate the safety and efficacy of non-invasive, non-radiating bioconductance measurements in distinguishing between malignant and benign lung lesions. No adverse events reported.

 
  Transcutaneous Computed Bioconductance Measurement in Lung Cancer Rex C. Yung, MD; Ming Ying Zeng, MD; Gregory J. Stoddard, MS; Michael Garff, BS; and Karleen Callahan, PhD. J Thorac Oncol. Vol. 7, No. 4, April 2012.

 

Transcutaneous Computed Bioconductance Measurement in Lung Cancer
Rex C. Yung, MD; Ming Ying Zeng, MD; Gregory J. Stoddard, MS; Michael Garff, BS; and Karleen Callahan, PhD.
J Thorac Oncol. Vol. 7, No. 4, April 2012.

 

Ongoing Trials

PL-208

The primary study hypothesis is that the ProLung Test will demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. A statistically significant result will indicate that patients with a high ProLung Test result have a greater risk of developing lung cancer than patients with a low test result.


 

If you have been diagnosed with an indeterminate pulmonary nodule, you may eligible to participate in the ProLung clinical trial. Fill out the form below and we will connect you to the nearest testing location.

Name *
Name
Phone
Phone